VICTORIA, Aug. 1, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES
LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB PINK:
IPATF) announces the launch of its High Value Target Scientific
Committee which will strengthen the scientific oversight and
methodological practice within Talem. The Committee consists of a
selection of internationally recognized visionary scientists and
experts from a broad range of disciplines. Their task is to assist
in the planning of Talem's partnerships, in particular, they are
charged with overseeing the development of the scientific pipeline
including reviewing and selecting potential targets for discovery,
evaluating partnerships with Biotech and Pharma companies, and
ensuring scientific rigor and best practices are adhered to.
![ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.) ImmunoPrecise Antibodies Ltd. (CNW Group/ImmunoPrecise Antibodies Ltd.)](https://mma.prnewswire.com/media/955317/ImmunoPrecise_Antibodies_Ltd__ImmunoPrecise_s_Wholly_Owned_Talem.jpg)
The composition of the committee, and supporting processes,
reflects a management-staff collaboration that ensures experience
and agreement on a common direction that will lead to a high level
of commitment and partnerships. The strategic plan will span three
years, from 2019–2022, with the aim of developing a robust pipeline
and established partnerships. Talem management, Dr. Jennifer Bath, will work closely with newly
elected Chairwoman, Dr. Ilse
Roodink.
Initial electees to the committee include Dr. Ilse Roodink (IPA
Europe), Dr. Zalan Szabo (U-Protein
Express, an IPA Company), Dr. Andra
Li (IPA Canada), and Dr. Jennifer
Bath (Talem, IPA Ltd). Future nominations are to be expected
as Talem continues to grow it's IP Estate.
About Talem Therapeutics
Talem Therapeutics (www.talemtherapeutics.com) is an
international biopharmaceutical company focused on the discovery
and development of new antibodies originating from IPA's innovative
and proprietary technologies and Structure-Based Drug Design
platform capabilities. Talem will focus on a broad pipeline of
partnered and in-house drug candidates in multiple therapeutic
areas including, but not limited to, neurology, immuno-oncology,
gastroenterology, inflammation, and rare/specialty diseases.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery
company focused on the next generation of antibody discovery, to
deliver the most therapeutically-relevant antibodies, in a shorter
period of time, with the highest probability of succeeding to
clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory
facilities located in Victoria, British Columbia, in collaboration with its
wholly-owned subsidiary operations at ImmunoPrecise Antibodies
Europe (formerly ModiQuest Research), in Oss, and U-Protein
Express, in Utrecht, both in the Netherlands. The Company operates globally to
offer a continuum of superior antibody services, from target
analysis to pre-clinical studies.
Forward Looking Information
This news release contains statements that, to the extent
they are not recitations of historical fact, may constitute
"forward-looking statements" within the meaning of applicable
Canadian securities laws. The Company uses words such as "may",
"would", "could", "will", "likely", "expect", "believe", "intend"
and similar expressions to identify forward-looking statements. Any
such forward-looking statements are based on assumptions and
analyses made by ImmunoPrecise in light of its experience and its
perception of historical trends, current conditions and expected
future developments. However, whether actual results and
developments will conform to ImmunoPrecise's expectations and
predictions is subject to any number of risks, assumptions and
uncertainties. Many factors could cause ImmunoPrecise's actual
results to differ materially from those expressed or implied by the
forward-looking statements contained in this news release. Such
factors include, among other things, actual revenues and earnings
for IPA being lower than anticipated, and those risks and
uncertainties described in ImmunoPrecise's annual management
discussion and analysis for the fiscal year ended April 30,
2018 which can be accessed at www.sedar.com. The
"forward-looking statements" contained herein speak only as of the
date of this press release and, unless required by applicable law,
ImmunoPrecise undertakes no obligation to publicly update or revise
such information, whether as a result of new information, future
events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE ImmunoPrecise Antibodies Ltd.